Polyendocrine metabolic ovarian syndrome (PMOS), a hormonal condition formerly known as polycystic ovary syndrome that affects 1 in 8 women worldwide, is showing early response to obesity medications like semaglutide, according to clinical data published in the journal Fertility and Sterility. Researchers led by Dr. Melanie Cree at Children’s Hospital Colorado found that GLP-1 receptor agonists not only promote weight loss but also lower testosterone, improve insulin resistance, and normalize ovulation, offering new therapeutic avenues for a disorder that has historically relied solely on basic symptom management such as birth control pills.
Clinical Trial Results for Semaglutide in PMOS Treatment
Early data from clinical trials testing GLP-1 receptor agonists on PMOS patients show measurable improvements in metabolic markers and physical symptoms, according to findings published in June in Fertility and Sterility. In a study led by Dr. Melanie Cree, eight out of 11 participants who completed the trial lost at least 10% of their body weight.
The median weight loss among those participants reached approximately 42 pounds, while the median drop in testosterone levels hit 52%. Furthermore, six trial participants experienced increased menstrual frequency, with four returning to regular monthly periods. Across three distinct studies led by Dr. Cree—testing semaglutide injections, semaglutide pills, and exenatide injections—patients on the therapy consistently lost more weight and showed sharper drops in blood sugar, insulin, and testosterone than control groups.
Pro Tip: Understanding Hormonal Drivers
Excess insulin travels directly to the ovaries, spurring them to produce higher amounts of testosterone, which drives symptoms like skipped periods, severe acne, and unwanted facial hair growth.
Patient Experiences and the Long Road to Diagnosis
For patients like 18-year-old college student Charlotte Touzalin of Colorado, receiving a definitive diagnosis of PMOS took years of medical runarounds. Touzalin struggled with weight gain, abnormal periods, and facial hair growth starting as a young teenager, while her mother, 43-year-old Anne Schultz, spent decades managing overlapping symptoms, ovarian problems, and numerous miscarriages before learning they both shared the condition.
During a 10-month study participation involving weekly semaglutide injections, Touzalin reported that her abnormal hair growth slowed, her periods normalized, and she stopped experiencing constant weight gain. “I became a happier version of myself,” Touzalin said, noting she felt full after eating for the first time. However, after completing the study, Touzalin lost access to free medication in June due to insurance hurdles, prompting her family to fight coverage denials.
Insurance and Off-Label Prescription Barriers
As researchers continue clinical evaluations globally, a growing number of physicians are prescribing GLP-1 medications “off-label” to manage PMOS symptoms. Dr. Rana Malek noted that she frequently utilizes these patients to help with weight loss.
Despite these clinical applications, insurance coverage remains a primary obstacle for patients. Because GLP-1 drugs lack formal regulatory approval for treating PMOS specifically, and some insurers decline coverage for obesity care altogether, many individuals who could benefit are priced out of treatment. Touzalin currently faces this exact barrier, while her mother actively evaluates drug company assistance programs to restart her daughter’s therapy.
Did You Know?
The condition was officially renamed from polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) earlier this year to shift the focus away from ovaries and cysts.
Frequently Asked Questions
What is PMOS?
PMOS stands for polyendocrine metabolic ovarian syndrome, a hormonal condition affecting approximately 1 in 8 women worldwide. It is driven primarily by insulin and testosterone.
How do GLP-1 drugs help treat PMOS?
According to clinical studies, GLP-1 receptor agonists promote weight loss while improving insulin resistance, hormone balance, and ovulation.
Are GLP-1 medications approved for PMOS?
What are the common side effects of GLP-1 treatments?
Doctors note that results vary, and these medications can cause side effects such as nausea and constipation. Additionally, weight can return if the patient stops taking the medication.
Stay Informed on Women’s Health Research
Subscribe to our newsletter for the latest updates on clinical trials, endocrinology advancements, and healthcare access policies.